Tyche Industries [TYCHE] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison

Tyche Industries

BSE
Loading...

Sun Pharmaceutical

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Tyche Industries wins in 9 metrics, Sun Pharmaceutical wins in 11 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricTyche IndustriesSun PharmaceuticalBetter
P/E Ratio (TTM)12.0137.73Tyche Industries
Price-to-Book Ratio0.995.42Tyche Industries
Debt-to-Equity Ratio0.003.26Tyche Industries
PEG Ratio-1.10-1.94Sun Pharmaceutical
EV/EBITDA5.9523.98Tyche Industries
Profit Margin (TTM)19.33%19.29%Tyche Industries
Operating Margin (TTM)11.77%24.34%Sun Pharmaceutical
EBITDA Margin (TTM)11.77%24.34%Sun Pharmaceutical
Return on Equity9.08%15.08%Sun Pharmaceutical
Return on Assets (TTM)8.42%11.87%Sun Pharmaceutical
Free Cash Flow (TTM)$78.21M$119.44BSun Pharmaceutical
Dividend Yield3.84%1.26%Tyche Industries
1-Year Return-21.30%-14.60%Sun Pharmaceutical
Price-to-Sales Ratio (TTM)2.347.28Tyche Industries
Enterprise Value$635.27M$3,678.87BSun Pharmaceutical
EV/Revenue Ratio1.016.84Tyche Industries
Gross Profit Margin (TTM)68.87%79.58%Sun Pharmaceutical
Revenue per Share (TTM)$62$224Sun Pharmaceutical
Earnings per Share (Diluted)$11.91$43.23Sun Pharmaceutical
Beta (Stock Volatility)0.180.28Tyche Industries
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Tyche Industries vs Sun Pharmaceutical Stock Performance Analysis

Loading Price Chart...

Tyche Industries
Sun Pharmaceutical
Tyche Industries Stock Overview | Sun Pharmaceutical Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Tyche Industries-0.73%4.95%4.61%-1.35%0.35%-25.64%
Sun Pharmaceutical-0.31%2.80%3.33%-2.89%-7.84%-13.69%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Tyche Industries-21.30%2.55%-47.15%160.00%585.85%427.68%
Sun Pharmaceutical-14.60%70.78%218.03%80.00%690.16%2,608.73%

News Based Sentiment: Tyche Industries vs Sun Pharmaceutical

Tyche Industries

News based Sentiment: NEGATIVE

September brought a mixed bag of results for Tyche Industries, with revenue growth offset by declining profits and a negative stock performance. The fluctuating valuation grade and bearish market trends suggest continued challenges for the company, making it a risky investment in the short term. The upcoming earnings report will be critical.

View Tyche Industries News Sentiment Analysis

Sun Pharmaceutical

News based Sentiment: MIXED

October was a mixed month for Sun Pharma, with a significant acquisition balanced against a decline in net profit. Positive analyst ratings and tariff news provide offsetting positive signals, making it a month of notable, but not overwhelmingly positive, developments for investors.

View Sun Pharmaceutical News Sentiment Analysis

Performance & Financial Health Analysis: Tyche Industries vs Sun Pharmaceutical

MetricTYCHESUNPHARMA
Market Information
Market Cap i₹1.47B₹4.01T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i3,4693,168,435
90 Day Avg. Volume i3,0992,778,768
Last Close₹143.00₹1,631.20
52 Week Range₹129.10 - ₹224.50₹1,548.00 - ₹1,952.25
% from 52W High-36.30%-16.45%
All-Time High₹349.90 (Aug 17, 2020)₹1,960.35 (Sep 30, 2024)
% from All-Time High-59.13%-16.79%
Growth Metrics
Quarterly Revenue Growth-0.18%0.10%
Quarterly Earnings Growth-0.11%-0.20%
Financial Health
Profit Margin (TTM) i0.19%0.19%
Operating Margin (TTM) i0.12%0.24%
Return on Equity (TTM) i0.09%0.15%
Debt to Equity (MRQ) i0.003.26
Cash & Liquidity
Book Value per Share (MRQ)₹144.76₹300.99
Cash per Share (MRQ)₹82.13₹108.88
Operating Cash Flow (TTM) i₹112.96M₹110.84B
Levered Free Cash Flow (TTM) i₹124.07M₹109.29B
Dividends
Last 12-Month Dividend Yield i3.84%1.26%
Last 12-Month Dividend i₹5.50₹21.00

Valuation & Enterprise Metrics Analysis: Tyche Industries vs Sun Pharmaceutical

MetricTYCHESUNPHARMA
Price Ratios
P/E Ratio (TTM) i12.0137.73
Forward P/E i24.7549.91
PEG Ratio i-1.10-1.94
Price to Sales (TTM) i2.347.28
Price to Book (MRQ) i0.995.42
Market Capitalization
Market Capitalization i₹1.47B₹4.01T
Enterprise Value i₹635.27M₹3.68T
Enterprise Value Metrics
Enterprise to Revenue i1.016.84
Enterprise to EBITDA i5.9523.98
Risk & Other Metrics
Beta i0.180.28
Book Value per Share (MRQ) i₹144.76₹300.99

Financial Statements Comparison: Tyche Industries vs Sun Pharmaceutical

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TYCHESUNPHARMA
Revenue/Sales i₹127.00M₹137.86B
Cost of Goods Sold i₹39.53M₹28.15B
Gross Profit i₹87.47M₹109.71B
Research & Development iN/AN/A
Operating Income (EBIT) i₹14.95M₹33.72B
EBITDA i₹37.14M₹47.66B
Pre-Tax Income i₹32.60M₹31.73B
Income Tax i₹8.28M₹8.70B
Net Income (Profit) i₹24.32M₹22.93B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TYCHESUNPHARMA
Cash & Equivalents i₹39.77M₹102.69B
Total Current Assets i₹1.21B₹526.24B
Total Current Liabilities i₹96.25M₹181.94B
Long-Term Debt i₹0₹3.58B
Total Shareholders Equity i₹1.37B₹724.86B
Retained Earnings i₹1.19B₹578.62B
Property, Plant & Equipment i₹68.16M₹100.36B

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TYCHESUNPHARMA
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTYCHESUNPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i3,4693,168,435
Average Daily Volume (90 Day) i3,0992,778,768
Shares Outstanding i10.25M2.40B
Float Shares i2.94M1.06B
% Held by Insiders i0.71%0.56%
% Held by Institutions i0.00%0.25%

Dividend Analysis & Yield Comparison: Tyche Industries vs Sun Pharmaceutical

MetricTYCHESUNPHARMA
Last 12-Month Dividend i₹5.50₹21.00
Last 12-Month Dividend Yield i3.84%1.26%
3-Year Avg Annual Dividend i₹3.00₹14.67
3-Year Avg Dividend Yield i1.41%0.46%
3-Year Total Dividends i₹9.00₹44.00
Ex-Dividend DateSep 19, 2025Jul 07, 2025